| Description |
Amivantamab (ami) is an EGFR-MET bispecific antibody with immune-cell directing activity. Lazertinib (laz) is a CNS-penetrant, 3rd-generation EGFR TKI. Cohort C of the CHRYSALIS-2 study (NCT04077463) enrolled pts with advanced NSCLC harboring atypical non-Ex20ins EGFR mutations who were treatment-naive or had less than or equal to 2 prior lines, which may include a 1st/2nd-generation EGFR TKI (Pts with Ex19del or L858R co-mutations were excluded). This combination was evaluated among pts with atypical EGFR-mutated advanced NSCLC in cohort C.As of 4 Dec 2023, 105 pts received ami+laz, with a median follow-up of 13.8 mo (range, 0.1 - 30.2), and ORR was 51% (95% CI, 41 - 61). To explore whether different EGFR mutations correlate with treatment outcomes, we collected baseline plasma samples and evaluated the EGFR mutation sites using Amoy 10 genes NGS assay. We observed the most common mutations were G719X (54%), L861Q (24%), and S768I (22%). |